UAS Laboratories, LLC (Wausau, Wisconsin, USA) has announced the acquisition of certain intellectual property assets of Micropharma Limited, Montreal, Canada, whose researchers have developed the award-winning probiotic strain, Lactobacillus reuteri NCIMB 30242 offered under the mark LRC and protected by two families of registered patents. The LRC strain has been shown to support healthy cholesterol levels and maintain heart health. As part of the agreement, UAS Labs also takes ownership of the Cardioviva brand of probiotics; formulations offered under the Cardioviva brand can be found at major retailers in the U.S. and Canada.

“We are extremely proud to have acquired this superb intellectual property from Micropharma as it furthers our company mission of being the leader in providing probiotic-based health solutions worldwide and for growing the condition-specific health benefits associated with these bacteria,” said UAS Labs President and CEO Kevin Mehring.

“UAS Labs and its experienced management team are perfectly positioned to advance not only the commercial success but also the scientific documentation around the LRC strain and the Cardioviva formulations,” added Micropharma CEO Ryan Jones.

For more information, visit uaslabs.com.